Breaking News

Major Pharma Companies and CROs Surveyed Have Adopted Digital Pathology

Initial deployment of legacy systems has paved the way for imminent shift to modern software needed to accelerate AI-powered drug R&D.

Nearly three-fourths of life sciences organizations surveyed have invested in digital pathology to advance drug research and development (R&D), according to new research commissioned by Proscia, a software company. According to the report, over half of these organizations (53%) still center their operations around legacy software systems primarily for basic image viewing despite growing adoption of artificial intelligence (AI) to accelerate the introduction of breakthrough therapeutics.  ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters